By Hendra Lukman 
The H5N1 strain of avian influenza, commonly known as bird flu, has transitioned from a concern primarily affecting wild bird populations to a significant public health threat, raising alarms about its potential for pandemic spread. First identified in the United States in 2014, the virus has since demonstrated an alarming capacity to adapt and spill over into farmed animals, most notably dairy cows in recent years, and subsequently into humans. The Centers for Disease Control and Prevention (CDC) reports that over 70 human cases of H5N1 have been documented in the U.S. since 2022, including two fatalities, underscoring the evolving danger posed by this pathogen. Scientists are increasingly concerned that the virus’s continued circulation among diverse animal reservoirs presents ongoing opportunities for genetic mutations that could enhance its transmissibility between humans, a critical step towards a potential global pandemic.
In response to this escalating threat, researchers at Washington University School of Medicine in St. Louis have developed a promising new vaccine candidate. This innovative vaccine is designed for intranasal delivery, offering an alternative to traditional intramuscular injections. Preliminary studies conducted on hamsters and mice have yielded encouraging results, demonstrating that the nasal vaccine effectively elicits robust immune responses and provides significant protection against H5N1 infection following exposure.
Addressing a Critical Vaccine Hurdle
A significant challenge in developing effective influenza vaccines, including those targeting avian strains, is the phenomenon of immune interference. Immunity acquired from previous seasonal flu infections or vaccinations can sometimes diminish the body’s response to novel flu vaccines. The Washington University team’s research has specifically addressed this issue, finding that their intranasal vaccine retains its efficacy even in animal models that had pre-existing immunity to other influenza strains. This finding is particularly crucial for broad public health application, as a substantial portion of the human population, excluding very young children, possesses some level of immune memory from past flu exposures.
The groundbreaking findings of this study were published on January 30, 2024, in the peer-reviewed journal Cell Reports Medicine.
"This particular version of bird flu has been around for some time, but the unique and totally unexpected event where it jumped across species into dairy cows in the United States was a clear sign that we should prepare for the event that a pandemic may occur," stated Jacco Boon, PhD, a professor in the WashU Medicine John T. Milliken Department of Medicine and co-senior author of the study. "Our vaccine to the nose and upper airway—not the shot-in-the-arm vaccine people are used to—can protect against upper respiratory infection as well as severe disease. This could provide better protection against transmission because it protects against infection in the first place."
The Evolution of Bird Flu Vaccine Technology
While an existing vaccine for H5N1 is available, its development predates the current circulating strains. It was designed using older virus subtypes and may not offer optimal protection against the contemporary H5N1 variants. Furthermore, its widespread availability has been limited. The Washington University team leveraged advanced nasal vaccine technology previously pioneered at their institution by co-authors Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine, and David T. Curiel, MD, PhD, a professor of radiation oncology. This platform has demonstrated success in other vaccine applications, including a COVID-19 vaccine that has been available in India since 2022 and received approval for clinical testing in the United States last year.
Engineering a Targeted Immune Response
The efficacy of any vaccine hinges on the immune system’s ability to swiftly recognize and neutralize the targeted pathogen. To achieve this with their H5N1 vaccine, Boon and co-author Eva-Maria Strauch, PhD, an associate professor of medicine specializing in antivirals and protein design, meticulously selected proteins from H5N1 strains known to infect humans. By identifying and utilizing conserved features within these viral proteins, they engineered an optimized antigen. The antigen is the specific component of a virus that triggers an immune response. This custom-designed antigen was then incorporated into a harmless, non-replicating adenovirus, which acts as a robust delivery vehicle for the vaccine. This antigen design and adenovirus delivery methodology closely mirrors the successful approach employed for the COVID-19 nasal vaccine.
Unprecedented Protection in Animal Models
In rigorous testing conducted on hamsters and mice, the intranasal H5N1 vaccine demonstrated remarkable efficacy, conferring near-complete protection against infection. As anticipated, established seasonal flu vaccines provided negligible defense against the highly pathogenic H5N1 avian influenza. In both animal models, the nasal spray vaccine outperformed the same vaccine delivered via a traditional intramuscular injection, highlighting the advantages of the intranasal route for respiratory pathogen protection.
Crucially, the vaccine maintained its high level of effectiveness even when administered at lower doses and when animals were subsequently exposed to substantial quantities of the virus. This suggests a significant margin of safety and efficacy, important considerations for widespread public health deployment.
Disrupting Transmission at the Source: Nose and Lungs
The intranasal administration of the vaccine generated potent immune responses throughout the body, with particularly pronounced activity observed in the nasal passages and the entire respiratory tract. Dr. Boon emphasized that this targeted delivery offers a substantial benefit over injected vaccines. By directly conferring immunity to the initial sites of viral entry and replication – the nose and lungs – the vaccine is expected to not only reduce the severity of illness but also significantly curtail the transmission of the virus.
"We’ve shown that this nasal vaccine delivery platform we conceived, designed and conducted initial testing on at WashU Medicine can prevent H5N1 infection from taking hold in the nose and lungs," explained Dr. Diamond, the study’s co-senior author. "Delivering vaccine directly to the upper airway where you most need protection from respiratory infection could disrupt the cycle of infection and transmission. That’s crucial to slowing the spread of infection for H5N1 as well as other flu strains and respiratory infections."
Further experimental analysis investigated the potential for interference from pre-existing immunity. The researchers found that the nasal vaccine continued to provide robust protection, even in the presence of prior influenza immunity. This is a critical advantage, given that most individuals over a certain age have encountered influenza viruses and developed some degree of immune memory.
The Path Forward for the Nasal H5N1 Vaccine
The research team is committed to advancing this promising vaccine candidate. Their next steps involve conducting further comprehensive studies in animal models and utilizing organoids that accurately mimic human immune tissue to gain deeper insights into the vaccine’s mechanisms and efficacy. Additionally, efforts are underway to develop updated versions of the vaccine. These next-generation formulations aim to further mitigate the impact of pre-existing seasonal flu immunity and to amplify antiviral immune responses, thereby enhancing overall protection.
The Cooperative Center for Human Immunology (U19AI181103) and the Center for Research on Structural Biology of Infectious Diseases (75N93022C00035) provided essential funding for this vital research.
It is important to note that the Boon laboratory has received funding from Novavax Inc. for the development of an influenza virus vaccine and unrelated funding support from AbbVie Inc. Dr. Diamond serves as a consultant for or sits on the Scientific Advisory Board of Inbios, IntegerBio, Akagera Medicines, GlaxoSmithKline, Merck, and Moderna. The Diamond laboratory has also received unrelated funding support through sponsored research agreements from Moderna. These disclosures are standard practice in scientific publications and are provided for transparency.
Broader Implications: A Proactive Stance Against Future Pandemics
The emergence and spread of H5N1 avian influenza into mammalian populations, including dairy cattle and, consequently, humans, represents a significant evolutionary leap for the virus. Historically, avian influenza strains have had limited human-to-human transmissibility, often resulting in isolated cases with severe outcomes. However, the recent widespread epizootic in dairy cows has created an unprecedented opportunity for the virus to acquire adaptations that could facilitate more efficient human transmission. The current U.S. outbreak has seen the virus spread across numerous states and affect various animal species, including poultry, cattle, and even cats, demonstrating its expanding host range.
The implications of such a development are profound. A highly transmissible H5N1 strain with retained virulence could overwhelm healthcare systems and lead to a pandemic with potentially devastating global health and economic consequences, far exceeding those experienced during the COVID-19 pandemic due to the higher intrinsic mortality rate of H5N1 in humans.
The development of effective vaccines is a cornerstone of pandemic preparedness. Traditional flu vaccines, while beneficial in mitigating seasonal flu severity, are often not designed to provide robust protection against highly pathogenic avian influenza strains. The limitations of existing H5N1 vaccines, coupled with the challenges of rapid scale-up and distribution, underscore the urgent need for innovative vaccine technologies.
The intranasal vaccine platform developed by the Washington University team offers several key advantages in this context. Firstly, its delivery method bypasses the need for trained medical personnel for administration, potentially enabling mass vaccination campaigns more efficiently, especially in resource-limited settings. Secondly, by inducing mucosal immunity in the respiratory tract, it aims to block viral entry and replication at the earliest possible stage, thereby not only protecting the individual but also significantly reducing the likelihood of transmission to others. This "sterilizing immunity" at the point of infection is a highly sought-after goal in vaccine development.
Furthermore, the vaccine’s demonstrated efficacy in animals with pre-existing flu immunity is a critical factor for its real-world application. This suggests that the vaccine’s immunogenicity is not unduly hampered by prior exposure to common seasonal influenza viruses, a common scenario for most of the global population. This feature enhances its potential utility as a broad-spectrum defense against novel influenza threats.
The ongoing monitoring of H5N1’s evolution and the proactive development of countermeasures, such as this promising nasal vaccine, are vital components of a robust global biosecurity strategy. The scientific community’s ability to rapidly identify emerging threats and translate research into effective preventative tools is paramount in safeguarding public health against the ever-present risk of novel infectious diseases. The success of this intranasal vaccine in preclinical trials represents a significant stride forward in this ongoing effort.
